Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit

REGENERON PHARMACEUTICALS, INC.

2026-Q1 EPS reported $6.75 revenue$3,605,400,000

Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.
Charge expected to reduce GAAP and non-GAAP diluted EPS by ~$0.81 each for Q1 2026.
Results are preliminary, subject to closing procedures; actuals may differ.
Regeneron does not forecast such charges due to transaction uncertainty.
Company reiterates non-GAAP measure excludes certain items not viewed as useful.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2026.

Period: first quarter 2026
Result: preliminary results

Exact text from the filing

Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-040661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.